Table 4.
The Relationship Between Cumulative Drug Dose and FRAX Score
| Exposure | Model 1 | Model 2 | Model 3 | Model 4 |
|---|---|---|---|---|
| β (95% CI) | β (95% CI) | β (95% CI) | β (95% CI) | |
| MOF | ||||
| Cumulative dose (per 100 mg.months increase) | −0.076 (−0.099, −0.052) | −0.068 (−0.090, −0.046) | −0.037 (−0.054, -0.012) | −0.035 (−0.056, −0.014) |
| HF | ||||
| Cumulative dose (per 100 mg.months increase) | −0.041 (−0.059, −0.022) | −0.034 (−0.052, −0.016) | −0.010 (−0.024, −0.010) | −0.007 (−0.027, −0.007) |
Notes: Model 1: no covariates were adjusted. Model 2: age, sex, BMI, and smoking status were adjusted. Model 3: Model 2 plus adjustment for serum potassium, PTH, serum calcium, serum phosphorus, and ALP. Model 4: Model 3 plus adjustment for the the use probability of spironolactone.
Abbreviations: MOF, major osteoporotic fracture; HF, hip fracture; β, regression coefficient; CI, confidence interval; BMI, body mass index; PTH, parathyroid hormone; ALP, alkaline phosphatase.